Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density.
OBJECTIVE
Celiac disease (CD) is a relatively common gastrointestinal disorder that can be asymptomatic. However, even among asymptomatic patients a long-term reduction in bone mineral density (BMD) is found. Excellent noninvasive screening tests for CD are now available. Studies using older screening techniques have suggested a 10-fold increased prevalence of CD among patients with low BMD, but this has not been confirmed with current testing methodology. We set out to confirm these prevalence estimates using antiendomysial antibody testing.


METHODS
A total of 100 consecutive patients referred to our outpatient endocrinology clinic for evaluation of idiopathic low BMD were studied. In addition to the routine evaluation, patients completed a symptom questionnaire and underwent serological testing for the presence of the IgA antiendomysial antibody (EMA). All patients with a positive EMA underwent small bowel biopsy and permeability studies.


RESULTS
EMA results were available on 96 patients; 78/96 patients were female and the mean age was 57 yr (range 18-86 yr). Seven of 96 (7.3% [95% CI 2.1-12.5%]) were EMA-positive, but all tests were low titer (< or = 1:20). However, none of the biopsies showed any histopathological features of CD, nor did EMA status correlate with any of the clinical or laboratory features assessed.


CONCLUSIONS
Despite a high rate of weakly positive antibody tests, our data do not support an increased prevalence of CD among asymptomatic patients referred for evaluation of low BMD. Without an increase over the background prevalence, the high cost of EMA testing argues against routine use of this test for screening of this population.
Mather
K J
KJ
Division of Gastroenterology, University of Calgary, Alberta, Canada.
Meddings
J B
JB
Beck
P L
PL
Scott
R B
RB
Hanley
D A
DA
D015502:Absorptiometry, Photon / Q000379:methods; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis; D015519:Bone Density / Q000276:immunology; D002446:Celiac Disease / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology; D015897:Comorbidity; D016001:Confidence Intervals; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology; D015995:Prevalence; D011336:Probability; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric
D000974:Antibodies, Antinuclear; D015415:Biomarkers; D007070:Immunoglobulin A